Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bendandi

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Expert Review of Anticancer Therapy|July 13, 2002
Role of anti-idiotype vaccines in the modern treatment of human follicular lymphomaM Bendandi
Leukemia|August 15, 2000
Anti-idiotype vaccines for human follicular lymphomaM Bendandi
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2001
Novel secondary Ig VH gene rearrangement and in-frame Ig heavy chain complementarity-determining region III insertion/deletion variants in de novo follicular lymphomaC Kobrin, M Bendandi, L Kwak
European Journal of Haematology|October 1, 1995
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphomaP L Zinzani, M Bendandi, S Tura
Leukemia & Lymphoma|August 1, 1994
Adult Burkitt's lymphoma: clinical and prognostic evaluation of 20 patientsP L Zinzani, F Gherlinzoni, M Bendandi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Indolent lymphoma: the pathologist's viewpointS A Pileri, P L Zinzani, P Went, et al.
Haematologica|March 1, 1996
FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphomaP L Zinzani, M Bendandi, F Gherlinzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1997
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphomaP L Zinzani, M Bendandi, M Magagnoli, et al.
Oncogene|May 29, 2007
Anti-idiotype antibodies in cancer treatmentA López-Díaz de Cerio, N Zabalegui, M Rodríguez-Calvillo, et al.
Current Pharmaceutical Design|January 30, 2010
Idiotype vaccines for human B-cell malignanciesS Inoges, A Lopez-Diaz de Cerio, E Soria, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Expert Review of Anticancer Therapy|July 13, 2002
Role of anti-idiotype vaccines in the modern treatment of human follicular lymphomaM Bendandi
Leukemia|August 15, 2000
Anti-idiotype vaccines for human follicular lymphomaM Bendandi
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2001
Novel secondary Ig VH gene rearrangement and in-frame Ig heavy chain complementarity-determining region III insertion/deletion variants in de novo follicular lymphomaC Kobrin, M Bendandi, L Kwak
European Journal of Haematology|October 1, 1995
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphomaP L Zinzani, M Bendandi, S Tura
Leukemia & Lymphoma|August 1, 1994
Adult Burkitt's lymphoma: clinical and prognostic evaluation of 20 patientsP L Zinzani, F Gherlinzoni, M Bendandi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Indolent lymphoma: the pathologist's viewpointS A Pileri, P L Zinzani, P Went, et al.
Haematologica|March 1, 1996
FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphomaP L Zinzani, M Bendandi, F Gherlinzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1997
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphomaP L Zinzani, M Bendandi, M Magagnoli, et al.
Oncogene|May 29, 2007
Anti-idiotype antibodies in cancer treatmentA López-Díaz de Cerio, N Zabalegui, M Rodríguez-Calvillo, et al.
Current Pharmaceutical Design|January 30, 2010
Idiotype vaccines for human B-cell malignanciesS Inoges, A Lopez-Diaz de Cerio, E Soria, et al.
Pageof 8